| Name | Title | Contact Details |
|---|
We Put Our Patients First We’re a dental collective that’s lead by doctors and on a mission to put people at the center of dentistry. Get in Touch Partnerships Get the Support You Deserve Join a collective of dentists who work together to create a dent...
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Assisted Living *Skilled Nursing* Short-term rehab* The Benedictine Health System is one of the largest Catholic senior living organizations in the country, operating more than 35 communities in five states. BHS is a mission-based, non-profit health system headquartered in Minnesota, sponsored by the Benedictine Sisters of St. Scholastica Monastery in Duluth. BHS provides complete senior living and care services for aging adults, including independent housing, assisted living, long-term skilled nursing care, short-term rehabilitation and memory care. Mission The Benedictine Health System is a Catholic, faith-based organization entrusted with advancing the life-enhancing senior care ministry of the Benedictine Sisters of Duluth, Minnesota. We witness to God`s love by creating compassionate communities providing support to those we serve to live fully and live well with special concern for the underserved and those in need. Vision Creating Benedictine Living Communities where health, wellness and choice come to life.
Cityblock was founded in 2017 as the first tech-driven provider for communities with complex needs. We deliver better care to where it`s needed most, investing upstream in highly personalized, prevention-oriented health and social care to ultimately drive down costs and improve outcomes. Our tech enables scale by bringing together practical information, coordination, and communication for our members and our care teams. We are adamant about building a radically better member experience for people living in lower-income neighborhoods that have never been prioritized.
Community Health Partnership of Illinois (CHP) is a non-profit organization that provides high quality, patient centered healthcare to uninsured, underserved, migrants, seasonal agricultural workers and their families across rural and urban communities...